Table 3.

Averaged Clinical Scores at Baseline and Change for Nusinersen Treatment Intervals

Treatment interval	HFMSE, median (IQR)/median difference (CI)	p Value	RULM, median (IQR)/median difference (CI)	p Value	ALSFRS-R, median (IQR)/median difference (CI)	p Value
T1–T4	11.5 (3.8 to 40.3)		19.0 (13.4 to 34.6)		32.8 (28.0 to 39.0)
T5–T8 vs T1–T4	0.6 (0.1 to 1.4)	0.017	0.9 (0.4 to 1.3)	<0.001	0.7 (0.4 to 1.0)	<0.001
T9–T12 vs T1–T4	0.4 (−0.7 to 1.5)	0.523	0.5 (−0.0 to 1.1)	0.070	0.4 (−0.1 to 1.0)	0.115
T13–T19 vs T1–T4	−0.1 (−1.3 to 1.4)	0.843	0.7 (−1.5 to 1.2)	0.057	0.1 (−0.8 to 0.9)	0.774

Abbreviations: ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised; HFMSE = Hammersmith Functional Motor Scale Expanded; IQR = interquartile range; RULM = Revised Upper Limb Module.

p Values are obtained by a paired Wilcoxon signed-rank test.